Back to Overview
Martin Fabry PhD
Martin Fabry finished his bachelor’s degree in molecular biomedicine at the University of Bonn in 2014 and moved to the US as a visiting scientist at Cold Spring Harbor Laboratory (New York, US) working on improving CRISPR/Cas9 technologies. Following completion of a master’s degree in life and medical sciences in 2016 with emphasis on molecular mechanisms of immunity, Martin started his PhD in Medical Sciences with Cancer Research UK at the University of Cambridge studying genome organisation and stability.
After graduating with his doctorate degree in 2020, Martin worked as postdoctoral fellow in computational biology at the Gurdon Institute and European Bioinformatics Institute (EBI) in Cambridge with focus on stem cell development and establishing new technologies for stem cell differentiation.
Martin joined IP2 in 2018 as scientific consultant and started as a patent attorney candidate in late 2021.
- Life Science 100%
What more there is to say...
In his leisure time Martin likes running, hiking, diving and rowing.
What moves me
G 2/21: The Desaster failed
After almost two years of waiting, the Enlarged Board of Appeal published their long-awaited - some would say feared - decision G 2/21 on March 23, 2023 (1). In a nut shell: the disaster fails. But in detail: What is it about? Briefly, about the question of the...
Biting the Bullet
With around 482.2 billion U.S. dollars, Apple will be the world's most valuable brand by brand value in 2022, according to the Best Global Brands ranking. In the ranking compiled by Interbrand, Microsoft only came in second place with more than 278 billion U.S....
Sunrise Period for the Unitary Patent started
On March 1, 2023, the sunrise period began, the 3-month phase before the start of the Unitary Patent and the Unified Patent Court on June 1, 2023. From now on, it is possible to file opt-out requests and thus exclude the jurisdiction of the UPC for existing EP...
Back to Overview